Sangeetha Sagar

Sangeetha Sagar leads IAVI’s efforts to rapidly advance the most promising vaccine and antibody candidates from the laboratory into clinical trials, accelerating the product development process.

Sagar has 29 years of experience in all aspects of chemistry, manufacturing, and controls (CMC) development and supply of vaccines, gene and cell therapy products, and mono and multi-specific antibodies and conjugates. Most recently, Sagar was the global head of biotherapeutics development and supply at Janssen, Johnson and Johnson, leading all aspects of end-to-end biotherapeutics development. Prior to that, she was at Sanofi Pasteur leading quality, CMC innovation, and the COVID vaccine initiative for the company. She was at Merck & Co., Inc for 22 years working in roles of increasing responsibility from “in the lab” to global leadership of BioProcess R&D for biologics.

Sagar has her Ph.D. in chemical engineering from Carnegie Mellon University and was a John E. Fogarty NIH post-doctoral fellow at the CNRS in Marseille, France.